个股
共 6,296 份研报 · 国内 4,037 · 国外 1,841
客户结构优化驱动增长
Growth driven by customer mix improvement
野村·2026-10-26·9 页·创业板
3Q26:中国云厂商AI投资驱动下的稳健增长(光迅科技 Accelink 002281.SZ)
3Q26: solid growth driven by China CSPs AI investment
野村·2026-10-26·6 页·A股
宣布决定扩大JSW JFE钢铁有限公司(JJSL)的产能
JFE Holdings (5411): Announces Decision to Expand Production Capacity at JSW JFE Steel Limited (JJSL)
摩根士丹利·2026-10-26·7 页·其它
投资者日前瞻:AI热潮可能高估了拐点到来时间
Investor Day Preview: AI excitement likely overshooting the timing of any inflection
摩根士丹利·2026-10-26·11 页·美股
开始取得进展,但代价如何?上调预期与目标价,但维持低配,向管理层提出10个问题
Starting to Win, But at What Cost? Raising Ests and PT But Stay Underweight, +10Qs For Management
摩根士丹利·2026-10-26·20 页·其它
增长的持续性
MKS Inc. (MKSI.O): Durability of growth
摩根士丹利·2026-10-26·15 页·美股
斯伦贝谢公司 NV:2026年第三季度业绩小幅超预期;关注2027年
Schlumberger NV (SLB.N): 3Q26: Modest Beat; Focus on 2027
摩根士丹利·2026-10-26·15 页·美股
微创医疗(0853.HK):治理重整或强化复牌路径
MicroPort (0853): Governance reset may strengthen the path to trade resumption
摩根大通·2026-10-26·9 页·港股
美国运通(AXP.US):业绩超预期得益于税收利好与准备金释放;但账单增速放缓与费用压力削弱本次财报亮点
American Express (AXP): Headline Beat Flattered by Tax and Reserve Release; Softer Billings and Expense Pressures Temper the Print
摩根大通·2026-10-26·20 页·美股
罗氏(ROP.S):2027年销售与核心EPS增长预期分别为低至中个位数及中至高个位数,与市场共识一致
Roche (ROP.S): 2027 growth expected to be in the low to mid-single-digit range for sales and mid to high single digit for Core EPS, which is captured by Consensus
摩根大通·2026-10-26·15 页·其它
罗珀科技(ROP,ROP US):三季度回顾:有机增长加速、并购前景改善,评级上调至"中性"
Roper Technologies (ROP): 3Q Review: Upgrade to Neutral as Organic Growth Accelerates and M&A Prospects Improve
摩根大通·2026-10-26·14 页·美股
罗林斯(ROL.US):2026年PestWorld大会核心要点:争夺AI发现技术主导权,并验证可量化疗效
Rollins (ROL): PestWorld 2026 Key Takeaway: The Race to Own AI Discovery and Prove Measurable Outcomes
摩根大通·2026-10-26·12 页·美股
OptiTROP-Lung06进一步验证sac-TMT一线PD-L1阴性非鳞NSCLC潜力
Kelun Biotech (6990.HK): OptiTROP-Lung06 further validates sac-TMT's 1L PD-L1-negative nsqNSCLC opportunity
摩根大通·2026-10-26·11 页·港股
康方生物(9926.HK):HARMONi-GI1数据积极但OS获益受强对照组限制;SSGJ-707支持PD-1/VEGF类药物交叉印证
Akeso (9926.HK): HARMONi-GI1 Positive but OS Upside Capped by Strong Control Arm; SSGJ-707 Supports PD-1/VEGF Class Read-Across
摩根大通·2026-10-26·10 页·港股
阿斯利康(AZN.L)ESMO 2026会议纪要:四项重大试验数据消除肿瘤业务约50亿美元增量销售风险
ESMO 2026 Takeaways: Data across 4 major trials de-risk c. $5bn in incremental sales for AZN's oncology franchise
摩根大通·2026-10-26·14 页·其它
ESMO 2026会议要点:Mo-Rez治疗PROC的Ib期更新数据疗效令人鼓舞,小幅利好
ESMO 2026 Takeaways: Updated Mo-Rez Phase Ib PROC data looks encouraging on efficacy, minor positive
摩根大通·2026-10-26·9 页·其它
美国战术衍生品策略:Take-Two互动——重返罪恶都市
Take-Two Interactive: Return to Vice City
摩根大通·2026-10-26·9 页·美股
美国运通:表面超预期得益于税收与准备金释放,账单增速走弱与费用压力削弱业绩成色
American Express: Headline Beat Flattered by Tax and Reserve Release; Softer Billings and Expense Pressures Temper the Print
摩根大通·2026-10-26·20 页·美股
大冢控股(4578):Vertex制药ASN 2026会议关键要点——我们认为Pove成为Voyxact竞争威胁的可能性有限
Otsuka Holdings (4578): Vertex Pharmaceuticals: Key takeaways from ASN 2026 event: We see limited likelihood that Pove will become a competitive threat to Voyxact
摩根大通·2026-10-26·9 页·其它
Veeva系统:投资者日前瞻:关键主题、前期要点及潜在催化剂
Veeva Systems (VEEV): Investor Day Preview: Key Themes, Prior Takeaways, and Potential Catalysts
摩根大通·2026-10-26·8 页·美股
显示 3421 - 3440 条,共 6,296 条